Results 1 to 10 of about 1,481,271 (307)

IFN-I inducible miR-3614-5p targets ADAR1 isoforms and fine tunes innate immune activation

Frontiers in Immunology, 2022
Regulation of innate immune responses is essential for maintenance of immune homeostasis and development of an appropriate immunity against microbial infection.
Françoise Vuillier, Françoise Vuillier, Zhi Li, Zhi Li, Iain Black, Iain Black, Melania Cruciani, Melania Cruciani, Erminia Rubino, Erminia Rubino, Frédérique Michel, Frédérique Michel, Sandra Pellegrini, Sandra Pellegrini   +13 more
doaj   +1 more source

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease

Nature Communications, 2022
Idiopathic multicentric Castleman disease (iMCD) is a life-threatening inflammatory disease requiring immediate intervention, for which the recommended first-line therapy is the Interleukin-6 pathway inhibitor siltuximab.
Sheila K. Pierson, Laura Katz, Reece Williams, Melanie Mumau, Michael Gonzalez, Stacy Guzman, Ayelet Rubenstein, Ana B. Oromendia, Philip Beineke, Alexander Fosså, Frits van Rhee, David C. Fajgenbaum   +11 more
doaj   +1 more source

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Scientific Reports, 2021
Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose
Anje Cauwels, Sandra Van Lint, Elke Rogge, Annick Verhee, Bram Van Den Eeckhout, Shengru Pang, Marco Prinz, Niko Kley, Gilles Uzé, Jan Tavernier   +9 more
doaj   +1 more source

Human Ubiquitin-Specific Peptidase 18 Is Regulated by microRNAs via the 3'Untranslated Region, A Sequence Duplicated in Long Intergenic Non-coding RNA Genes Residing in chr22q11.21

Frontiers in Genetics, 2021
Ubiquitin-specific peptidase 18 (USP18) acts as gatekeeper of type I interferon (IFN) responses by binding to the IFN receptor subunit IFNAR2 and preventing activation of the downstream JAK/STAT pathway.
Erminia Rubino, Erminia Rubino, Melania Cruciani, Nicolas Tchitchek, Nicolas Tchitchek, Anna Le Tortorec, Antoine D. Rolland, Önay Veli, Leslie Vallet, Giulia Gaggi, Frédérique Michel, Nathalie Dejucq-Rainsford, Sandra Pellegrini   +12 more
doaj   +1 more source

Role of FK506-sensitive signals in asthmatic lung inflammation

Frontiers in Immunology, 2022
Asthma is airway inflammatory diseases caused by the activation of group 2 innate lymphoid cells (ILC2s) and type 2 helper T (TH2) cells. Cysteine proteases allergen cause tissue damage to airway epithelial cells and activate ILC2-mediated type 2 airway ...
Chihiro Tomiaki, Kosuke Miyauchi, Sewon Ki, Yoshie Suzuki, Narumi Suzuki, Hiroshi Morimoto, Yohei Mukoyama, Masato Kubo, Masato Kubo   +8 more
doaj   +1 more source

Comparison of the Seven Interleukin-32 Isoforms’ Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity

Frontiers in Immunology, 2022
Cytokines are significantly associated with the homeostasis of immune responses in health and disease. Interleukin-32 (IL-32) is a cytokine originally discovered in natural killer cell transcript 4.
Saerok Shim, Siyoung Lee, Yasmin Hisham, Sinae Kim, Sinae Kim, Tam T. Nguyen, Tam T. Nguyen, Afeisha S. Taitt, Jihyeong Hwang, Hyunjhung Jhun, Ho-Young Park, Youngmin Lee, Su Cheong Yeom, Sang-Yeob Kim, Yong-Gil Kim, Soohyun Kim, Soohyun Kim   +16 more
doaj   +1 more source

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment

Frontiers in Immunology, 2021
BackgroundInterferon beta (IFNβ) has been prescribed as a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) for nearly three decades.
Priyanka Devi-Marulkar, Priyanka Devi-Marulkar, Carolina Moraes-Cabe, Carolina Moraes-Cabe, Pascal Campagne, Béatrice Corre, Béatrice Corre, Aida Meghraoui-Kheddar, Aida Meghraoui-Kheddar, Vincent Bondet, Alba Llibre, Darragh Duffy, Elisabeth Maillart, Caroline Papeix, Sandra Pellegrini, Sandra Pellegrini, Frédérique Michel, Frédérique Michel   +17 more
doaj   +1 more source

A Paradoxical Effect of Interleukin-32 Isoforms on Cancer

Frontiers in Immunology, 2022
IL-32 plays a contradictory role such as tumor proliferation or suppressor in cancer development depending on the cancer type. In most cancers, it was found that the high expression of IL-32 was associated with more proliferative and progression of ...
Saerok Shim, Siyoung Lee, Siyoung Lee, Yasmin Hisham, Sinae Kim, Sinae Kim, Tam T. Nguyen, Tam T. Nguyen, Afeisha S. Taitt, Jihyeong Hwang, Hyunjhung Jhun, Ho-Young Park, Youngmin Lee, Su Cheong Yeom, Sang-Yeob Kim, Yong-Gil Kim, Soohyun Kim, Soohyun Kim   +17 more
doaj   +1 more source

Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies

EMBO Molecular Medicine, 2020
Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index.
Leander Huyghe, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uzé, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert, Jan Tavernier   +16 more
doaj   +1 more source

Glucocorticoid Receptor-mediated transactivation is hampered by Striatin-3, a novel interaction partner of the receptor

Scientific Reports, 2017
The transcriptional activity of the glucocorticoid receptor (GR) is co-determined by its ability to recruit a vast and varying number of cofactors. We here identify Striatin-3 (STRN3) as a novel interaction partner of GR that interferes with GR’s ligand ...
Ioanna Petta, Nadia Bougarne, Jolien Vandewalle, Lien Dejager, Sofie Vandevyver, Marlies Ballegeer, Sofie Desmet, Jonathan Thommis, Lode De Cauwer, Sam Lievens, Claude Libert, Jan Tavernier, Karolien De Bosscher   +12 more
doaj   +1 more source